Related Experiment Video

Updated: Jul 20, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K

Evolving landscape of targeted treatment options for HER2-positive gastric/gastroesophageal adenocarcinomas

Raisa Epistola1, Joseph Chao2, Jennifer Lee1

  • 1Harbor-UCLA Medical Center, Division of Hematology and Medical Oncology, Torrance, California.

Clinical Advances in Hematology & Oncology : H&O
|August 2, 2023
PubMed

Insights

Human epidermal growth factor receptor 2 (HER2)-targeted therapies improve outcomes for patients with HER2-positive gastric and gastroesophageal cancers. This review covers HER2 testing, treatment strategies, and future directions.

Area of Science:

  • Oncology
  • Gastroenterology

Background:

  • Gastric and gastroesophageal adenocarcinomas are aggressive cancers with limited treatment options.
  • Human epidermal growth factor receptor 2 (HER2) expression is a key biomarker in a subset of these tumors.

Purpose of the Study:

  • To review the clinical trials and contemporary use of HER2-targeted therapies in gastric and gastroesophageal cancers.
  • To discuss challenges in HER2 testing and patient selection.
  • To highlight ongoing research in novel HER2-directed treatments.

Main Methods:

  • Literature review of key clinical trials and studies.
  • Analysis of current guidelines and testing methodologies for HER2 status.
  • Summary of ongoing clinical investigations.

Main Results:

  • HER2-targeted treatments have demonstrated improved outcomes in both localized and advanced settings for HER2-positive patients.
  • Current HER2 testing methods have limitations, impacting optimal patient identification.
  • Novel combinations and agents are under investigation to further enhance efficacy.

Conclusions:

  • HER2-targeted therapy is a crucial component of treatment for HER2-positive gastric and gastroesophageal adenocarcinomas.
  • Improving HER2 testing accuracy and exploring new therapeutic strategies are essential for advancing patient care.

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.2K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
114
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
198
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
110
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K